Edition:
United States

Neuren Pharmaceuticals Ltd (NEU.AX)

NEU.AX on Australia Stock Exchange

0.06AUD
26 May 2017
Change (% chg)

$0.00 (+1.69%)
Prev Close
$0.06
Open
$0.06
Day's High
$0.06
Day's Low
$0.06
Volume
631,588
Avg. Vol
1,866,910
52-wk High
$0.09
52-wk Low
$0.04

Latest Key Developments (Source: Significant Developments)

Neuren Pharmaceuticals says received $1 mln research and development tax incentive
Monday, 3 Apr 2017 09:01pm EDT 

Neuren Pharmaceuticals Ltd : Asx alert-Neuren receives $1 million research and development tax incentive-NEU.AX .Received cash of approximately $1 million under Australian Research And Development Tax Incentive Program.  Full Article

Neuren Pharmaceuticals says IRSF confirms financial support for Neuren's clinical trials
Monday, 12 Oct 2015 06:48pm EDT 

Neuren Pharmaceuticals:Says that the International Rett Syndrome Foundation (Rettsyndrome.org) has made a financial commitment of up to US$1 million, to continue its support of Neuren's clinical trials of trofinetide for the treatment of Rett syndrome.  Full Article

Neuren Pharmaceuticals updates on progress in orphan drug programs
Wednesday, 29 Jul 2015 02:16am EDT 

Neuren Pharmaceuticals Ltd:Orphan drug designation for trofinetide in both rett syndrome and fragile x syndrome recommended by European medicines agency.Enrolment completed in fragile x phase 2 clinical trial; top-line results expected in December 2015.Says anticipates that the European commission will provide formal confirmation of these designations in August 2015.Says to propose to FDA a design for a single phase 3 clinical trial to support a new drug application for rett syndrome.  Full Article

More From Around the Web